Potential nondopaminergic drugs for Parkinson's disease
- Author
- SILVERDALE, Monty A1 ; FOX, S. H2 ; CROSSMAN, A. R3 ; BROTCHIE, J. M3
[1] Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester, United Kingdom
[2] Motac Neuroscience Ltd., Manchester, United Kingdom
[3] Walton Centre for Neurology and Neurosurgery, Fazakerley, Liverpool, United Kingdom - Issue title
- Parkinson's Disease
- Author (monograph)
- GORDIN, Ariel (Editor)1 ; KAAKKOLA, Seppo (Editor)2 ; TERÄVÄINEN, Heikki (Editor)2
[1] Research Centre, Orion Pharma, Orionintie 1, 02100 Espoo, Finland
[2] Department of Neurology, University of Helsinki, Helsinki, Finland - Source
Advances in neurology. 2003, Vol 91, pp 273-291, 19 p ; ref : 183 ref
- Publisher
- Lippincott - Raven, New York, NY
/
Lippincott - Raven, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antiparkinsonien Chimiothérapie Homme Parkinson maladie Traitement Encéphale pathologie Extrapyramidal syndrome Maladie dégénérative Système nerveux central pathologie Système nerveux pathologie
- Keyword (en)
- Antiparkinson agent Chemotherapy Human Parkinson disease Treatment Cerebral disorder Extrapyramidal syndrome Degenerative disease Central nervous system disease Nervous system diseases
- Keyword (es)
- Antiparkinsoniano Quimioterapia Hombre Parkinson enfermedad Tratamiento Encéfalo patología Extrapiramidal síndrome Enfermedad degenerativa Sistema nervosio central patología Sistema nervioso patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02B Neuropharmacology / 002B02B06 Anticonvulsants. Antiepileptics. Antiparkinson agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17G Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
- Discipline
- Neurology Pharmacological treatments Psychopathology. Psychiatry. Clinical psychology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 14986419
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:55:\"Potential nondopaminergic drugs for Parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Advances in neurology\";s:9:\"\u0000*\u0000stitle\";s:11:\"Adv. neurol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"273\";s:8:\"\u0000*\u0000epage\";s:3:\"291\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0091-3952\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SILVERDALE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Monty A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:9:\"FOX, S. H\";i:1;s:14:\"CROSSMAN, A. R\";i:2;s:14:\"BROTCHIE, J. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ADNRA3\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:19:\"Parkinson's Disease\";s:8:\"\u0000*\u0000title\";s:55:\"Potential nondopaminergic drugs for Parkinson's disease\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Lippincott - Raven\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"19\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:55:\"Potential nondopaminergic drugs for Parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Advances in neurology\";s:9:\"\u0000*\u0000stitle\";s:11:\"Adv. neurol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"273\";s:8:\"\u0000*\u0000epage\";s:3:\"291\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0091-3952\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SILVERDALE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Monty A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:9:\"FOX, S. H\";i:1;s:14:\"CROSSMAN, A. R\";i:2;s:14:\"BROTCHIE, J. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ADNRA3\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:19:\"Parkinson's Disease\";s:8:\"\u0000*\u0000title\";s:55:\"Potential nondopaminergic drugs for Parkinson's disease\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Lippincott - Raven\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"19\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:55:\"Potential nondopaminergic drugs for Parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Advances in neurology\";s:9:\"\u0000*\u0000stitle\";s:11:\"Adv. neurol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"273\";s:8:\"\u0000*\u0000epage\";s:3:\"291\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0091-3952\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SILVERDALE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Monty A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:9:\"FOX, S. H\";i:1;s:14:\"CROSSMAN, A. R\";i:2;s:14:\"BROTCHIE, J. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ADNRA3\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:19:\"Parkinson's Disease\";s:8:\"\u0000*\u0000title\";s:55:\"Potential nondopaminergic drugs for Parkinson's disease\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Lippincott - Raven\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"19\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:55:\"Potential nondopaminergic drugs for Parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Advances in neurology\";s:9:\"\u0000*\u0000stitle\";s:11:\"Adv. neurol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"273\";s:8:\"\u0000*\u0000epage\";s:3:\"291\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0091-3952\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SILVERDALE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Monty A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:9:\"FOX, S. H\";i:1;s:14:\"CROSSMAN, A. R\";i:2;s:14:\"BROTCHIE, J. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ADNRA3\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:19:\"Parkinson's Disease\";s:8:\"\u0000*\u0000title\";s:55:\"Potential nondopaminergic drugs for Parkinson's disease\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Lippincott - Raven\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"19\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:55:\"Potential nondopaminergic drugs for Parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Advances in neurology\";s:9:\"\u0000*\u0000stitle\";s:11:\"Adv. neurol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"273\";s:8:\"\u0000*\u0000epage\";s:3:\"291\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0091-3952\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SILVERDALE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Monty A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:9:\"FOX, S. H\";i:1;s:14:\"CROSSMAN, A. R\";i:2;s:14:\"BROTCHIE, J. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ADNRA3\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:19:\"Parkinson's Disease\";s:8:\"\u0000*\u0000title\";s:55:\"Potential nondopaminergic drugs for Parkinson's disease\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Lippincott - Raven\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"19\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
